Literature DB >> 22551309

Why dapsone stops seizures and may stop neutrophils' delivery of VEGF to glioblastoma.

R E Kast1, F Lefranc, G Karpel-Massler, M-E Halatsch.   

Abstract

Lopez-Gomez et al. recently published remarkable but mechanistically unexplained empirical evidence that the old antibiotic dapsone has antiepileptic activity. We addressed the question "Why should a sulfone antibiotic reduce seizures?". We report here our conclusions based on data from past studies that seizures are associated with elevated interleukin-8 (IL-8) and that dapsone inhibits IL-8 release and function in several different clinical and experimental contexts. Diverse CNS insults cause an increase in CNS IL-8. Thus, the pro-inflammatory environment generated by increase IL-8 leads to a lower seizure threshold. Together this evidence indicates dapsone exerts anti-seizure activity by diminishing IL-8 signalling. Since IL-8 is clearly upregulated in glioblastoma and contributes to the florid angiogenesis of that disease, and since interference with IL-8 function has been shown to inhibit glioblastoma invasion and growth in several experimental models, and dapsone has been repeatedly been shown to clinically inhibit IL-8 function when used to treat human neutrophilic dermatoses, we believe that dapsone thereby reduces seizures by countering IL-8 function and may similarly retard glioblastoma growth by such anti-IL-8 function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22551309     DOI: 10.3109/02688697.2012.674577

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  10 in total

1.  Dioscin alleviates lipopolysaccharide-induced acute lung injury through suppression of TLR4 signaling pathways.

Authors:  Chuntao Wang; Qingnian Li; Tianyu Li
Journal:  Exp Lung Res       Date:  2020-01-14       Impact factor: 2.459

Review 2.  Dapsone in dermatology and beyond.

Authors:  Gottfried Wozel; Christian Blasum
Journal:  Arch Dermatol Res       Date:  2013-12-06       Impact factor: 3.017

3.  Anti-glioma Activity of Dapsone and Its Enhancement by Synthetic Chemical Modification.

Authors:  Georg Karpel-Massler; Richard E Kast; Markus D Siegelin; Annika Dwucet; Elisabeth Schneider; Mike-Andrew Westhoff; Christian Rainer Wirtz; Xiao Yun Chen; Marc-Eric Halatsch; Carsten Bolm
Journal:  Neurochem Res       Date:  2017-08-29       Impact factor: 3.996

4.  Antioxidant, anticonvulsive and neuroprotective effects of dapsone and phenobarbital against kainic acid-induced damage in rats.

Authors:  Araceli Diaz-Ruiz; Marisela Mendez-Armenta; Sonia Galván-Arzate; Joaquín Manjarrez; Concepción Nava-Ruiz; Iván Santander; Gustavo Balderas; Camilo Ríos
Journal:  Neurochem Res       Date:  2013-06-01       Impact factor: 3.996

Review 5.  Toward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ Regimen.

Authors:  Michael E Salacz; Richard E Kast; Najmaldin Saki; Ansgar Brüning; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Onco Targets Ther       Date:  2016-04-27       Impact factor: 4.147

6.  Research Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation.

Authors:  Richard E Kast
Journal:  Med Sci (Basel)       Date:  2021-02-16

7.  Specific Treatment Exists for SARS-CoV-2 ARDS.

Authors:  Badar Kanwar; Chul Joong Lee; Jong-Hoon Lee
Journal:  Vaccines (Basel)       Date:  2021-06-10

8.  Commentary for the Elderly in the Pandemic Era.

Authors:  Asif Khattak; Badar Kanwar; Consolato Sergi; Chul Joong Lee; Jenny Balentine; Jong-Hoon Lee; Jungwuk Park; So Jeong Lee; Su-Hee Choi
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2021-06-10

9.  Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness.

Authors:  R E Kast
Journal:  Springerplus       Date:  2015-10-23

Review 10.  Dapsone, More than an Effective Neuro and Cytoprotective Drug.

Authors:  Araceli Diaz-Ruiz; Juan Nader-Kawachi; Francisco Calderón-Estrella; Alfonso Mata-Bermudez; Laura Alvarez-Mejia; Camilo Ríos
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.